Vaccination against meningococcal disease in Europe: Review and recommendations for the use of conjugate vaccines

139Citations
Citations of this article
64Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

At the end of 2005, six European countries had implemented public immunization campaigns with serogroup C conjugate vaccines, and all had experienced substantial declines in the incidence of serogroup C disease. A quadrivalent ACWY meningococcal vaccine is in use in the USA, but serogroup A is extremely rare in Europe and serogroups Y and W135 are infrequent causes of disease. This paper outlines recommendations on the use of conjugate vaccines in Europe based on the experience with meningococcal C conjugate (MCC) vaccines so far. © 2006 Federation of European Microbiological Societies.

Cite

CITATION STYLE

APA

Trotter, C. L., & Ramsay, M. E. (2007, January). Vaccination against meningococcal disease in Europe: Review and recommendations for the use of conjugate vaccines. FEMS Microbiology Reviews. https://doi.org/10.1111/j.1574-6976.2006.00053.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free